Syntara Limited · ASX:SNT
Syntara — Shareholder Meeting (November 2023)
13 slides from Syntara's shareholder meeting presentation, Nov 28, 2023
Slide 1: Presentation by Chief Executive Officer
Presentation by Chief Executive Officer 2023 AGM| 28 November 2023 Gary Phillips CEO
Slide 2: Investor Presentation
™ Investor Presentation Gary Phillips, CEO November 2023
Slide 3: Pharmaxis evolves to Syntara: Cost savings and clear focus
Pharmaxis evolves to Syntara1: Cost savings and clear focus energise Syntara clinical programs The main factors impacting cash from separation Proforma Cash Expenses 2023 of the mannitol business unit are: 35,000 • Employee numbers dropping from ~70 to ~25 30,000 • Much reduced new lease for researc
Slide 4: A clinical stage drug development company
A clinical stage Prioritising haematological Three further phase drug development malignancies with high unmet 1c/2 investigator company need: initiated or externally Myelofibrosis (MF) funded clinical studies • Market opportunities in excess of to deliver results in US$1b per annum high unmet need
Slide 5: Experienced senior management team
Experienced senior management team Scientific excellence Significant global experience in drug development, commercialisation and partnering • Global leaders in amine oxidase chemistry Gary Phillips Jana Baskar and biology – key to Chief Executive Officer Chief Medical Officer inflammatory and fibro
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered 2 drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis PXS-5505 in Oncology Oral and topical pan-LO
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications Myelofibrosis • Treatment with lysyl oxidase inhibitor Myelodysplastic significantly Syndrome reduced reticulin • In xenograft fibrosis and mouse model that megakaryocyte closely resembles cell number in human disease, GATA
Slide 8: Potential for five trials to deliver near term value
Potential for five trials to deliver near term value Pipeline creates multiple opportunities in high value markets Drug Upcoming Addressable Indication Phase Trial design Status Candidate Milestones market (US$) • Open label 12 month study (n=15) First 2H 2024: Myelofibrosis • MF patients receiving
Slide 9: News flow
News flow Recent and anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points Q4 2023 H1 2024 H2 2024 • PXS-5505 phase 2a myelofibrosis • PXS-5505 phase 2a myelofibrosis • PXS-5505 phase 2a combination study (add on to JAK combination
Slide 10: Shareholders & Cash
Shareholders & Cash Financial Information 30 Sept 23 Institutional Ownership 30 Sept 23 ASX Code1 PXS BVF Partners LP 14% Karst Peak Capital Limited 12% Share price $0.033 D&A Income Limited 11% Liquidity (turnover last 12 months) 124m shares Platinum Investment Management 8% Limited Market Cap A$26
Slide 11: Financial Overview
Financial Overview 2023 AGM| 28 November 2023 David McGarvey CFO developing breakthrough treatments for fibrosis and inflammation
Slide 12: Financials: Sale of MBU – impact on income statement
Financials Sale of MBU – impact on income statement Expense Pro Forma Cash Expenses 2023 Reductions 2023 Core expenses Employee costs (before share payments) (10,516) 4,859 (5,657) Administration & corporate (2,706) 1,037 (1,669) Occupancy & utilities (1,480) 1,321 (159) Sales, marketing & distribut
Slide 13: Financials: Sale of MBU – impact on balance sheet
Financials Sale of MBU – impact on balance sheet 30-Sep Indicative Cash 7,145 7,145 R&D tax credit net of loan 805 805 Accounts receivable 3,484 - No investment required in working capital Inventory 2,527 - No investment required in working capital Security deposit 1,023 200 Reduced secured rental g